EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure

Kristina Charaya, Dmitry Shchekochikhin, Anna Agadzhanyan, Maria Vashkevich, Maria Chashkina, Valeri Kulikov, Denis Andreev

Cardiorenal Medicine · 2023 · 101-108

DOI: 10.1159/000529614 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiorenal Medicine, online erschienen am 20.02.2023. Verfasst von Kristina Charaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sechenov University, Department of Cardiology, Functional and Ultrasound Diagnostics, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Hyponatremia, Heart Failure. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The dynamics of serum sodium are important in acute heart failure (AHF), and hyponatremia is associated with a poor prognosis. The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on serum sodium concentrations in AHF is unknown.

Methods

In a single-centre, controlled, randomized study, patients were prescribed dapagliflozin in addition to standard treatment during the first 24 h of hospitalization versus standard treatments. The pre-specified outcome was an absolute change in plasma sodium concentrations between randomization (first 24 h after admission) and discharge. The secondary outcomes were an absolute change in serum sodium concentrations within 48 h of randomization and the persistence of hyponatremia.

Results

The sample comprised 285 patients (53% males; average age 73.26 ± 13 years); 140 of these were randomized to the dapagliflozin group. The average ejection fraction was 46 ± 14%; 155 patients (54%) had ischaemic heart failure; and 35% had diabetes mellitus. Median N-terminal pro b-type natriuretic peptide was 4,225 [2,120; 9,105] pg/mL. The average estimated glomerular filtration rate was 53.9 ± 17.2 mL/min. Hospital mortality was 6.7%. At randomization, serum sodium concentrations were 139.8 ± 4.32 mmol/L in the dapagliflozin group versus 140.85 ± 4.04 mmol/L in the control group; p = 0.048. 48 h later, there was an increase in serum sodium in the dapagliflozin group (2 [−2; 4] mmol/L), as compared to the control group (−1 [−3.75; 2]); p < 0.001. This was accompanied by equilibration of the sodium levels between the groups (141.08 ± 4.08 mmol/L in the dapagliflozin group vs. 140.05 ± 4.82 mmol/L in the control group; p = 0.096). At the time of discharge, there was no difference in serum sodium concentrations (140.98 ± 4.77 mmol/L vs. 139.86 ± 4.45 mmol/L; p = 0.082). The increase in serum sodium concentrations during the period of observation [randomization; discharge] was small but statistically significant in the dapagliflozin group (1 [−3; 3.75] mmol/L vs. −2 [−4.5; 2] mmol/L; p = 0.015). Of 36 patients (21 in the dapagliflozin group and 15 in the control group) with baseline hyponatraemia, this persisted in 6 (16.6%) in the dapagliflozin group and in 11 (73.3%) in the control group (p = 0.008).

Conclusion

The use of dapagliflozin in AHF is associated with a tendency to the increase in serum sodium concentrations and lesser persistence of hyponatremia. This effect occurred within the first 48 h and persisted until discharge. The impact of dapagliflozin on serum sodium was more pronounced in patients with hyponatremia at randomization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyponatremiaHeart FailureMaleHumansMiddle AgedAgedAged, 80 and overFemaleGlucosidesSodiumBenzhydryl Compounds

Stichwörter der Autor:innen

Acute heart failureDapagliflozinHyponatremia

Substanzen

GlucosidesSodiumdapagliflozinBenzhydryl Compounds

Autor:innen und Institutionen

  • Sechenov University, Department of Cardiology, Functional and Ultrasound Diagnostics, Moscow, Russian Federation.

Zitieren

APA

Charaya, K., Shchekochikhin, D., Agadzhanyan, A., Vashkevich, M., Chashkina, M., Kulikov, V., & Andreev, D. (2023). Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure. Cardiorenal Medicine, 101-108. https://doi.org/10.1159/000529614

Vancouver

Charaya K, Shchekochikhin D, Agadzhanyan A, Vashkevich M, Chashkina M, Kulikov V, et al. Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure. Cardiorenal Medicine. 2023:101-108. doi:10.1159/000529614

BibTeX
@article{Charaya2023,
  author = {Charaya, Kristina and Shchekochikhin, Dmitry and Agadzhanyan, Anna and Vashkevich, Maria and Chashkina, Maria and Kulikov, Valeri and Andreev, Denis},
  title = {Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure},
  journal = {Cardiorenal Medicine},
  year = {2023},
  pages = {101--108},
  doi = {10.1159/000529614}
}
Kostenlos starten →